Global Polycystic Ovary Syndrome (PCOS) Market Study, 2015-2026: Key Marketed & Pipeline Drugs, Clinical Trials, Patent Information, 10-Year Disease Incidence Forecast, Licensing & Acquisition Deals - ResearchAndMarkets.com
Retrieved on:
Monday, March 30, 2020
This Market Spotlight report covers the Polycystic Ovary Syndrome market, comprising key pipeline and marketed drugs, clinical trials, patent information, and a 10-year disease prevalence forecast, as well as licensing and acquisition deals.
Key Points:
- This Market Spotlight report covers the Polycystic Ovary Syndrome market, comprising key pipeline and marketed drugs, clinical trials, patent information, and a 10-year disease prevalence forecast, as well as licensing and acquisition deals.
- The approved drugs in the PCOS space target estrogen receptor 1, androgen receptor, and follicle stimulating hormone receptor.
- Therapies in the pipeline for PCOS focus on targets such as AMP-activated protein kinase, neurokinin receptor, and gonadotropin-releasing hormone receptor.
- Merck KGaA leads industry sponsors with the highest overall number of clinical trials for PCOS, followed by AstraZeneca and Merck & Co.